Hybrid Thoracoscopic Surgical and Transvenous Catheter Ablation versus Repeated Transvenous Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation - HARTCAP-AF

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•The patient is must be a candidate for an interventional treatment strategy and
•* Known with a history of symptomatic persistent AF (continuous AF lasting > 7
•days) or longstanding persistent AF (continuous AF lasting > 1 year),
•* Refractory to or intolerant of at least one antiarrhythmic drug class I or
•* At least 18 years of age,
•* Mentally able and willing to give informed consent.

•* Referred specifically for a hybrid ablation,
•* Previous ablation procedure,
•* Longstanding persistent AF > 3 years,
•* Paroxysmal atrial fibrillation,
•* AF secondary to electrolyte imbalance, thyroid disease, or other reversible
•or non-cardiovascular cause,
•* Presence of left atrial appendage (LAA) thrombus,
•* Left atrial size * 60mm (PLAX-view on TEE),
•* Left ventricular ejection fraction < 40%,
•* In need for other cardiac surgery then AF treatment within 12 months,
•* Intolerance to heparin and warfarin,
•* Unable to undergo TEE,
•* Sick-sinus-syndrome
•* Mitral valve insufficiency > Iº
•* Carotid stenosis > 80%,
•* Active infection or sepsis,
•* Pleural adhesions,
•* Elevated hemi diaphragm
•* Significant pulmonary dysfunction as assessed by preoperative lung testing,
•* Chronic obstructive pulmonary disease with a FEV1 or VC < 50% predicted,
•* History of cerebrovascular accident (CVA) or transient ischemic attack (TIA),
•* History of blood clotting abnormalities,
•* History of thoracic radiation,
•* History of pericarditis,
•* History of cardiac tamponade,
•* History of thoracotomy or cardiac surgery,
•* Body-mass-index > 40,
•* Pregnancy,
•* Life expectancy less than 12 months,
•* Participation in any other clinical study involving an investigational drug

发起方

Medisch Universitair Ziekenhuis Maastricht